Attana (ATANA) Q4 2024 earnings summary

Executive summary

• Focused on biosensor development, consumables, and research services for biotech and pharma sectors; listed on NGM Nordic SME since 2018.

• 2024 marked by capital raises, loan repayments, and a CEO transition; net proceeds from new share issues totaled 6.9 MSEK in January and 10 MSEK in November.

• Notable customer upgrades and scientific publications; ongoing diagnostic collaborations and successful product validation.

Financial highlights

• Net sales for 2024 were 4.1 MSEK, down from 5.1 MSEK year-over-year.

• Operating loss improved to -10.0 MSEK from -12.4 MSEK; net loss after tax was -12.8 MSEK versus -13.8 MSEK prior year.

• Earnings per share improved to -0.0195 SEK from -0.0506 SEK year-over-year.

• Cash flow from operations was -7.2 MSEK, an improvement from -11.5 MSEK; period-end cash position at 1.6 MSEK.

• Other operating income increased to 0.6 MSEK from 0.3 MSEK year-over-year.

Outlook and guidance

• 2025 focus on existing customers with clear decision-making paths, aiming for profitability within the year.

• Plans to expand sales through customer networks in 2026 and target larger organizations by 2027 with a clear ROI proposition.

• Diagnostic projects and product validation efforts continue, with expectations for increased sales and cash stability.